Uncertainties persist amid optimism over Genting's Alzheimer's drug trial result – The Edge Malaysia
- Uncertainties persist amid optimism over Genting’s Alzheimer’s drug trial result The Edge Malaysia
- Genting’s 20%-owned TauRx says new data on Alzheimer’s drug show sustained benefits The Edge Malaysia
- Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx’s LUCIDITY Trial Business Wire
- Maybank IB advises investors to look at Genting given its involvement in life sciences New Straits Times
- AD/PD 2024: TauRx’s HMTM promising despite lacking primary endpoint data Pharmaceutical Technology
Source: Business News Feed